Markets Cantor ups Collegium Pharma to OW; PT to $26 from $17 Cantor Fitzgerald upgraded Collegium Pharmaceuticals (NASDAQ:COLL) to “overweight” from “neutral” and raised its price target to $26 from $17, citing its agreement to acquire BioDelivery Sciences International. Shares... February 14, 2022